Decibel Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) announced participation in several virtual investor conferences in September 2021. CEO Laurence Reid will host fireside chats at H.C. Wainwright's 23rd Annual Global Investment Conference on September 13 and Baird's 2021 Global Healthcare Conference on September 14. The company will also engage in investor meetings at Citi's 16th Annual BioPharma Virtual Conference on September 10 and SVB Leerink's CybeRx Series on September 22-23. Webcasts will be available on their website.

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the Company will participate in the following upcoming virtual investor conferences in September.

Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in fireside chats at:

• H.C. Wainwright’s 23^rd Annual Global Investment Conference: Fireside chat on Monday, September 13, 2021 at 7:00 a.m. E.T.
• Baird’s 2021 Global Healthcare Conference: Fireside chat on Tuesday, September 14, 2021 at 4:20 p.m. E.T. The session will be available via live webcast to conference attendees.

Management will participate in investor meetings at:

• Citi’s 16^th Annual BioPharma Virtual Conference: Investor meetings on Friday, September 10, 2021.
• SVB Leerink’s CybeRx Series: Neuromuscular, Rare Diseases and Genetic Medicines 1x1 Event on Wednesday, September 22, 2021 and Thursday, September 23, 2021.

A webcast of the H.C. Wainwright fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter. 

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936

FAQ

What conferences will Decibel Therapeutics participate in September 2021?

Decibel Therapeutics will participate in H.C. Wainwright's conference on September 13, Baird's conference on September 14, Citi's conference on September 10, and SVB Leerink's CybeRx Series on September 22-23.

Who will represent Decibel Therapeutics at the investor conferences?

CEO Laurence Reid will represent Decibel Therapeutics during the fireside chats at the conferences.

What is the date of the fireside chat at H.C. Wainwright's conference?

The fireside chat at H.C. Wainwright's conference is scheduled for September 13, 2021, at 7:00 a.m. E.T.

When can I access the webcast of the H.C. Wainwright fireside chat?

The webcast can be accessed on Decibel Therapeutics' website, and an archived replay will be available for approximately 90 days after the presentation.

What is the focus of Decibel Therapeutics' business?

Decibel Therapeutics focuses on developing transformative treatments to restore and improve hearing and balance.